Vaccine ID:

Name:
DTaP

Pathogen:
The bacteria: *Corynebacterium diphtheriae*, *Bordetella pertussis* and *Clostridium tetani*

Class:
Subunit – toxoid - inactivated toxin

Produced from:
Bacterial culture media

Inactivation:
Diphtheria & tetanus toxins are treated with formaldehyde, Pertussis antigens with formaldehyde or other fixatives

Adjuvants:
250-500 micrograms of aluminum salt per antigen

Schedule:
Immunization at 2 months. Boosts at 4, 6, 15-20 months & 4-6 years

Contains:
Produced by several companies. Generally, these vaccines contain: diphtheria toxoid, tetanus toxoid, and 10-25 micrograms of inactivated pertussis toxin [e.g., 5-25 micrograms of filamentous hemagglutinin, 3-8 micrograms of pertactin and 5 micrograms fimbriae types 2 and 3]. The vaccine may also contain various salts and residual formaldehyde.



Approval date:
DTP was one of the first combination vaccines to be licensed by the FDA and it integrated into the routine vaccination schedule in the late 1940s.

The first vaccines was successful in preventing three severe diseases, however, it contained whole cell pertussis which was associated with rare but serious neurological defects. Therefore, in 1991, the FDA approved a new vaccine, DTaP, which contained only a few select antigens of pertussis, was successful in inducing immunity and had to neurological side-effects.